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OBJECTIVES: The purpose of the study was to compare quality
of life (QoL) between patients with atrial ﬁbrillation (AF) treated
medically and patients who underwent catheter ablation.
METHODS: The study group consisted of 363 pts (104 females,
aged 63  11 years), who were admitted to 3 hospitals within a
period of 6 months. The patients were divided into two groups
according to the treatment modality: 243 patients were treated
medically (group 1), and 120 patients underwent catheter abla-
tion (1.2 procedures per patient) (group 2). All patients ﬁlled in
a questionnaire of QoL EQ-5D at baseline and 1 year after the
index hospitalization. Subjective QoL was evaluated using the
0–100% scale. Objective QoL was assessed using the set of VAS
RESULTS: Baseline subjective QoL was 54  14% in group 1 vs.
63  11% in group 2 (P < 0.001). Baseline objective QoL was
59  14% in group 1 vs. 66  12% in group 2 (P < 0.001).
After 1 year, subjective QoL improved to 58  18% in group 1,
and to 78  14% in group 2 (P < 0.001). Objective QoL
improved to 63  16% in group 1, and to 84  14% in group 2
(P < 0.001). When the patients in groups 1 and 2 were asked to
compare their current heath status with that one year ago, they
responded as follows: much better—8 (3%) vs. 64 (53%),
(P < 0.001); slightly better—35 (14%) vs. 37 (31%), (P < 0.01);
same—57 (24%) vs. 16 (13%), (P = 0.08); slightly worse—117
(48%) vs. 3 (3%), (P < 0.001); and much worse—26 (11%) vs.
0, (P =< 0.001). CONCLUSIONS: One year after the index hos-
pital admission for AF, signiﬁcant increase in subjective and
objective QoL was observed in patients who underwent catheter
ablation compared to the patients treated medically.
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OBJECTIVES: To derive Australian utility values for different
health states associated with acute coronary syndromes (ACS)
for use in an economic model. METHODS: The study focused
on 12 chronic ACS speciﬁc health states which describe varia-
tions in conditions related to myocardial infarction, stroke
severity, treatment side-effects of gastrointestinal bleeding, and
their appropriate treatments. Health states were developed
based on expert clinical opinion and were presented alone and
in combination. A total of 86 participants took part in the
research. They ranged in age from 20–82 years (mean age 50.1
years). Participants were presented with information about
stroke, myocardial infarction, gastrointestinal bleeding, and
their treatments. They were then shown 12 health states
describing differing severity and combinations of ACS events
and associated treatment and were asked to value these using a
standard gamble technique. To minimise cognitive overload, the
health states were presented to participants in a random order.
RESULTS: The results showed that participants successfully
valued the health states applying values derived for the main
three stroke health states in a logical sequence. Utility values
ranged from 0.80 (SD = 0.24) for mild stroke, 0.63 (SD = 0.24)
for moderate stroke, and 0.47 (SD = 0.31) for a patient who
had experienced a severe stroke. When myocardial infarction
was added to these three scenarios the returned utility values for
mild, moderate and severe stroke decreased to 0.72 (SD = 0.25),
0.59 (SD = 0.26) and 0.43 (SD = 0.31) respectively. When
gastrointestinal bleeding was also added, the mild and severe
stroke health states decreased to 0.68 (SD = 0.27) and 0.42
(SD = 0.32) respectively, while the moderate stroke health state
remained unchanged. CONCLUSIONS: Results were internally
consistent, with the more severe health states valued with a
poorer utility value. Of note, treatment side effects are relativity
insigniﬁcant when cardiovascular events are considered. Utility
results affect the burden of ACS outcomes.
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OBJECTIVES: Although atrial ﬁbrillation (AF) is associated
with increased morbidity and mortality related to heart failure,
stroke and other thromboembolic complications, there is limited
data on its effects on patients’ health-related quality of life
(HRQoL). The objective was to analyse the factors determining
utility in patients with all types of AF, both at baseline and after
one year from inclusion, based on data from the Euro Heart
Survey on AF. METHODS: HRQoL was measured with the
EQ-5D questionnaire, providing a utility score. At baseline,
5050 AF patients in 35 European countries had completed all
dimensions of the EQ-5D, and 3045 had done so after one year.
We used Powell’s censored least absolute deviations estimator
(CLAD) for inference and ordinary least squares (OLS) regres-
sions for prediction. Variables with strong correlation (0.6)
were omitted and insigniﬁcant variables removed stepwise from
the CLAD regressions (95% CI). OLS regressions were per-
formed on the difference in utility between baseline and follow-
up. RESULTS: The mean utility per patient at baseline was
0.753 (SD 0.269), compared to 0.783 (SD 0.249) at follow-up.
Regardless of time point, utility and change in utility were sig-
niﬁcantly correlated with age, gender, AF type and symptoms. At
baseline, utility was also determined by domestic status, regular
exercise habits, diabetes and comorbidities. At follow-up,
additional determinants included geographic region, underlying
heart disease, baseline utility, and adverse events. Change in
utility over time was affected by the baseline variables age,
gender, geographic region, regular exercise habits, comorbidities,
heart failure symptoms, utility, and adverse events during
follow-up. CONCLUSIONS: Utility in AF patients at baseline
and over time is inﬂuenced by demographic and disease-speciﬁc
variables, mainly gender and the modiﬁable factors symptom
burden, AF type, comorbidities and adverse events. These ﬁnd-
ings provide useful information on the effect of AF on HRQoL
and input for economic evaluations.
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